Title ANGPTL 2 activity in cardiac pathologies accelerates heartfailure by perturbing cardiac function and energy metabolism
暂无分享,去创建一个
K. Otsu | T. Murohara | K. Fukuda | Y. Oike | I. Manabe | N. Takeda | S. Tohyama | M. Endo | M. Takeya | K. Terada | J. Wada | M. Sano | K. Miyata | Hiroyuki Fukushima | J. Yamashita | S. Mohri | T. Okumura | K. Araki | Y. Komohara | Y. Ujihara | T. Kadomatsu | H. Sakaguchi | J. Morinaga | Jiabin Zhao | T. Sugizaki | Satoshi Yamaguchi | Shunshun Zhu | Michio Sato | Haruki Horiguchi | Zhe Tian | Taichi Sugizaki
[1] T. Ninomiya,et al. Serum Angiopoietin–Like Protein 2 Is a Novel Risk Factor for Cardiovascular Disease in the Community: The Hisayama Study , 2016, Arteriosclerosis, thrombosis, and vascular biology.
[2] K. Naruse,et al. Induced NCX1 overexpression attenuates pressure overload-induced pathological cardiac remodelling. , 2016, Cardiovascular research.
[3] M. Suematsu,et al. Glutamine Oxidation Is Indispensable for Survival of Human Pluripotent Stem Cells. , 2016, Cell metabolism.
[4] Y. Oike,et al. Angiopoietin-like protein 2 increases renal fibrosis by accelerating transforming growth factor-β signaling in chronic kidney disease. , 2016, Kidney international.
[5] F. Wang,et al. [Role of calcineurin-nuclear factor of activated T cells signaling pathway in myoblast apoptosis induced by cyclic tensile strain]. , 2015, Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology.
[6] Yen-Wen Wu,et al. Serum Angiopoietin-Like Protein 2 Concentrations Are Independently Associated with Heart Failure , 2015, PloS one.
[7] R. Hui,et al. MicroRNA-221 inhibits autophagy and promotes heart failure by modulating the p27/CDK2/mTOR axis , 2014, Cell Death and Differentiation.
[8] Vassilios J. Bezzerides,et al. Abstract 238: miR-222 is Necessary for Exercise-induced Cardiac Growth and Protects Against Pathological Cardiac Remodeling , 2014 .
[9] M. Oshimura,et al. Reprogramming Suppresses Premature Senescence Phenotypes of Werner Syndrome Cells and Maintains Chromosomal Stability over Long-Term Culture , 2014, PloS one.
[10] M. Nakano,et al. Serum ANGPTL2 Levels Reflect Clinical Features of Breast Cancer Patients: Implications for the Pathogenesis of Breast Cancer Metastasis , 2014, The International journal of biological markers.
[11] Y. Oike,et al. Diverse roles of ANGPTL2 in physiology and pathophysiology , 2014, Trends in Endocrinology & Metabolism.
[12] G. Santulli. Angiopoietin-Like Proteins: A Comprehensive Look , 2014, Front. Endocrinol..
[13] N. Mochizuki,et al. The Secreted Protein ANGPTL2 Promotes Metastasis of Osteosarcoma Cells Through Integrin α5β1, p38 MAPK, and Matrix Metalloproteinases , 2014, Science Signaling.
[14] HisaoOgawa,et al. Role of Endothelial Cell–Derived Angptl2 in Vascular Inflammation Leading to Endothelial Dysfunction and Atherosclerosis Progression , 2014 .
[15] Y. Oike,et al. The angiotensin II AT1 receptor-associated protein Arap1 is involved in sepsis-induced hypotension , 2013, Critical Care.
[16] J. Molkentin. Parsing Good Versus Bad Signaling Pathways in the Heart: Role of Calcineurin–Nuclear Factor of Activated T-Cells , 2013, Circulation research.
[17] S. Takanashi,et al. Perivascular adipose tissue-secreted angiopoietin-like protein 2 (Angptl2) accelerates neointimal hyperplasia after endovascular injury. , 2013, Journal of molecular and cellular cardiology.
[18] T. Murohara,et al. Usefulness of serum cardiac troponins T and I to predict cardiac molecular changes and cardiac damage in patients with hypertrophic cardiomyopathy. , 2013, International heart journal.
[19] T. Ninomiya,et al. Angiopoietin-Like Protein 2 and Risk of Type 2 Diabetes in a General Japanese Population , 2012, Diabetes Care.
[20] A. Rosenzweig,et al. Can Exercise Teach Us How to Treat Heart Disease? , 2012, Circulation.
[21] G. Lopaschuk,et al. Agonist-Induced Hypertrophy and Diastolic Dysfunction Are Associated With Selective Reduction in Glucose Oxidation: A Metabolic Contribution to Heart Failure With Normal Ejection Fraction , 2012, Circulation. Heart failure.
[22] R. Hui,et al. MiR‐221 promotes cardiac hypertrophy in vitro through the modulation of p27 expression , 2012, Journal of cellular biochemistry.
[23] Y. Oike,et al. Macrophage-Derived Angiopoietin-Like Protein 2 Accelerates Development of Abdominal Aortic Aneurysm , 2012, Arteriosclerosis, thrombosis, and vascular biology.
[24] M. Nakano,et al. Tumor cell-derived angiopoietin-like protein ANGPTL2 is a critical driver of metastasis. , 2012, Cancer research.
[25] I. Komuro,et al. p53-induced adipose tissue inflammation is critically involved in the development of insulin resistance in heart failure. , 2012, Cell metabolism.
[26] S. Hirakawa,et al. Angiopoietin-like protein 2 is an important facilitator of inflammatory carcinogenesis and metastasis. , 2011, Cancer research.
[27] T. Prolla,et al. Mitochondrial Oxidative Stress Mediates Angiotensin II–Induced Cardiac Hypertrophy and G&agr;q Overexpression–Induced Heart Failure , 2011, Circulation research.
[28] 魚崎 英毅,et al. Efficient and scalable purification of cardiomyocytes from human embryonic and induced pluripotent stem cells by VCAM1 surface expression , 2011 .
[29] G. Fonarow,et al. Epidemiology and risk profile of heart failure , 2011, Nature Reviews Cardiology.
[30] M. Kasuga,et al. Angiopoietin-like protein 2 promotes chronic adipose tissue inflammation and obesity-related systemic insulin resistance. , 2009, Cell metabolism.
[31] S. Miyano,et al. Ligand-based gene expression profiling reveals novel roles of glucocorticoid receptor in cardiac metabolism. , 2009, American journal of physiology. Endocrinology and metabolism.
[32] I. Kasman,et al. PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. , 2009, Cancer cell.
[33] M. Cheitlin,et al. Outcome of Heart Failure with Preserved Ejection Fraction in a Population-Based Study , 2008 .
[34] L. Opie,et al. Metabolic mechanisms in heart failure. , 2007, Circulation.
[35] G. Jennings,et al. DIFFERENCES BETWEEN PATHOLOGICAL AND PHYSIOLOGICAL CARDIAC HYPERTROPHY: NOVEL THERAPEUTIC STRATEGIES TO TREAT HEART FAILURE , 2007, Clinical and experimental pharmacology & physiology.
[36] I. Komuro,et al. p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload , 2007, Nature.
[37] I. Shiojima,et al. Regulation of cardiac growth and coronary angiogenesis by the Akt/PKB signaling pathway. , 2006, Genes & development.
[38] T. Otsuki,et al. Exercise training improves aging-induced downregulation of VEGF angiogenic signaling cascade in hearts. , 2006, American journal of physiology. Heart and circulatory physiology.
[39] R. Schwartz,et al. Cardiac-Specific Deletion of Gata4 Reveals Its Requirement for Hypertrophy, Compensation, and Myocyte Viability , 2006, Circulation research.
[40] T. Suda,et al. Cooperative interaction of Angiopoietin-like proteins 1 and 2 in zebrafish vascular development. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[41] E. Levin,et al. Estrogen Inhibits Cardiomyocyte Hypertrophy in Vitro , 2005, Journal of Biological Chemistry.
[42] Christoph Handschin,et al. Metabolic control through the PGC-1 family of transcription coactivators. , 2005, Cell metabolism.
[43] S. Umemura,et al. The novel angiotensin II type 1 receptor (AT1R)‐associated protein ATRAP downregulates AT1R and ameliorates cardiomyocyte hypertrophy , 2005, FEBS letters.
[44] Frank J Giordano,et al. Oxygen, oxidative stress, hypoxia, and heart failure. , 2005, The Journal of clinical investigation.
[45] V. Gross,et al. Inflammatory mediators in chronic inflammatory bowel diseases , 1991, Klinische Wochenschrift.
[46] A. Itai,et al. A novel IKKbeta inhibitor stimulates adiponectin levels and ameliorates obesity-linked insulin resistance. , 2004, Biochemical and biophysical research communications.
[47] J. Huss,et al. Nuclear receptor signaling and cardiac energetics. , 2004, Circulation research.
[48] James M. Allen,et al. Systemic delivery of genes to striated muscles using adeno-associated viral vectors , 2004, Nature Medicine.
[49] Robert G Weiss,et al. Is the failing heart energy starved? On using chemical energy to support cardiac function. , 2004, Circulation research.
[50] D. Kass,et al. What Mechanisms Underlie Diastolic Dysfunction in Heart Failure? , 2004, Circulation research.
[51] M. Chandler,et al. Energy Metabolism in the Normal and Failing Heart: Potential for Therapeutic Interventions , 2002, Heart Failure Reviews.
[52] C. Croce,et al. Mechanism of Enhanced Cardiac Function in Mice with Hypertrophy Induced by Overexpressed Akt* , 2003, Journal of Biological Chemistry.
[53] S. Orlov,et al. Type 1 angiotensin II receptor-associated protein ARAP1 binds and recycles the receptor to the plasma membrane. , 2003, Biochemical and biophysical research communications.
[54] D. J. Veldhuisen,et al. The Imbalance Between Oxygen Demand and Supply as a Potential Mechanism in the Pathophysiology of Heart Failure: The Role of Microvascular Growth and Abnormalities , 2003, Microcirculation.
[55] P. Doevendans,et al. Requirement of Nuclear Factor of Activated T-cells in Calcineurin-mediated Cardiomyocyte Hypertrophy* , 2002, The Journal of Biological Chemistry.
[56] D. Kelly,et al. p38 Mitogen-activated Protein Kinase Activates Peroxisome Proliferator-activated Receptor α , 2001, The Journal of Biological Chemistry.
[57] S. Sasayama,et al. Calcineurin-GATA4 Pathway Is Involved in β-Adrenergic Agonist-responsive Endothelin-1 Transcription in Cardiac Myocytes* , 2001, The Journal of Biological Chemistry.
[58] G. Dorn,et al. Cytoplasmic signaling pathways that regulate cardiac hypertrophy. , 2001, Annual review of physiology.
[59] E. Lakatta,et al. Culture and adenoviral infection of adult mouse cardiac myocytes: methods for cellular genetic physiology. , 2000, American journal of physiology. Heart and circulatory physiology.
[60] G. Koh,et al. Molecular Cloning, Expression, and Characterization of Angiopoietin-related Protein , 1999, The Journal of Biological Chemistry.
[61] K. Chien,et al. Stress Pathways and Heart Failure , 1999, Cell.
[62] E. Olson,et al. Cardiac hypertrophy: sorting out the circuitry. , 1999, Current opinion in genetics & development.
[63] B. Lorell,et al. Selective changes in cardiac gene expression during compensated hypertrophy and the transition to cardiac decompensation in rats with chronic aortic banding. , 1993, Circulation research.
[64] C. Stevens,et al. Aquaporin 4 and glymphatic flow have central roles in brain fluid homeostasis , 2021, Nature Reviews Neuroscience.
[65] J. Gulick,et al. Isolation and characterization of the mouse cardiac myosin heavy chain genes. , 1991, The Journal of biological chemistry.
[66] J. Gwathmey,et al. Abnormal intracellular calcium handling, a major cause of systolic and diastolic dysfunction in ventricular myocardium from patients with heart failure. , 1990, Circulation.
[67] C. Kawai,et al. Report of the WHO/ISFC task force on the definition and classification of cardiomyopathies. , 1980, British heart journal.
[68] S. Katsuki. [Hisayama study]. , 1971, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine.